Sun Pharmaceutical Industries Share Price
Sector: Biotechnology & Drugs
1453.25 -6.90 (-0.47%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1451.15
Today’s High
1495.55
52 Week Low
946.8
52 Week High
1638.7
1453.05 -6.75 (-0.46%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1451
Today’s High
1498
52 Week Low
946.4
52 Week High
1638.85
Key Metrics
- Market Cap (In Cr) 350254.9
- Beta 0.73
- Div. Yield (%) 0.92
- P/B 5.5
- TTM P/E 40.62
- Peg Ratio 2.51
- Sector P/E 34.04
- D/E 0.05
- Open Price 1490.05
- Prev Close 1460.15
Sun Pharmaceutical Industries Analysis
Price Analysis
-
1 Week-1.81%
-
3 Months-6.38%
-
6 Month18.56%
-
YTD15.91%
-
1 Year47.8%
Risk Meter
- 20% Low risk
- 20% Moderate risk
- 20% Balanced Risk
- 20% High risk
- 20% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 9
- 10
- 14
- 15
- Buy
- 12
- 12
- 11
- 12
- Hold
- 7
- 7
- 5
- 5
- Sell
- 2
- 2
- 1
- 1
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 30
- 31
- 31
- 33
Sun Pharmaceutical Industries News
Sun Pharmaceutical Industries Q4 Results Live : profit rise by 33.77% YOY
1 min read . 23 May 2024Stocks to watch: Sun Pharma, Adani Ports, IREDA, Hitachi Energy, BHEL
6 min read . 22 May 2024Sun Pharmaceutical Industries Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 48496.85
- Selling/ General/ Admin Expenses Total
- 9429.06
- Depreciation/ Amortization
- 2556.64
- Other Operating Expenses Total
- 15418.18
- Total Operating Expense
- 38560.81
- Operating Income
- 9936.04
- Net Income Before Taxes
- 11087.89
- Net Income
- 9576.38
- Diluted Normalized EPS
- 41.69
- Period
- 2024
- Total Assets
- 85462.88
- Total Liabilities
- 21796.13
- Total Equity
- 63666.75
- Tangible Book Valueper Share Common Eq
- 193.39
- Period
- 2024
- Cashfrom Operating Activities
- 12136.27
- Cashfrom Investing Activities
- -690.2
- Cashfrom Financing Activities
- -6710.16
- Net Changein Cash
- 4661.92
- Period
- 2023
- Total Revenue
- 43885.68
- Selling/ General/ Admin Expenses Total
- 19394.87
- Depreciation/ Amortization
- 2529.43
- Other Operating Expenses Total
- 738.24
- Total Operating Expense
- 34793.33
- Operating Income
- 9092.35
- Net Income Before Taxes
- 9408.43
- Net Income
- 8473.58
- Diluted Normalized EPS
- 36.01
- Period
- 2023
- Total Assets
- 80743.59
- Total Liabilities
- 24748.21
- Total Equity
- 55995.38
- Tangible Book Valueper Share Common Eq
- 158.19
- Period
- 2023
- Cashfrom Operating Activities
- 5526.02
- Cashfrom Investing Activities
- -7943.68
- Cashfrom Financing Activities
- 2376.07
- Net Changein Cash
- 115.48
- Period
- 2022
- Total Revenue
- 38654.49
- Selling/ General/ Admin Expenses Total
- 15945.42
- Depreciation/ Amortization
- 2143.74
- Other Operating Expenses Total
- 709.74
- Total Operating Expense
- 35076.82
- Operating Income
- 3577.67
- Net Income Before Taxes
- 4481.32
- Net Income
- 3272.73
- Diluted Normalized EPS
- 28.03
- Period
- 2022
- Total Assets
- 69807.77
- Total Liabilities
- 21796.55
- Total Equity
- 48011.22
- Tangible Book Valueper Share Common Eq
- 146.82
- Period
- 2022
- Cashfrom Operating Activities
- 9025.99
- Cashfrom Investing Activities
- -5724.74
- Cashfrom Financing Activities
- -5193.46
- Net Changein Cash
- -1764.78
- Period
- 2021
- Total Revenue
- 33498.14
- Selling/ General/ Admin Expenses Total
- 14344.76
- Depreciation/ Amortization
- 2079.95
- Other Operating Expenses Total
- 734.39
- Total Operating Expense
- 31351.52
- Operating Income
- 2146.62
- Net Income Before Taxes
- 2799.37
- Net Income
- 2903.82
- Diluted Normalized EPS
- 26.71
- Period
- 2021
- Total Assets
- 67666.73
- Total Liabilities
- 21203.95
- Total Equity
- 46462.78
- Tangible Book Valueper Share Common Eq
- 143.85
- Period
- 2021
- Cashfrom Operating Activities
- 6170.37
- Cashfrom Investing Activities
- 536.22
- Cashfrom Financing Activities
- -5980.48
- Net Changein Cash
- 596.42
- Period
- 2020
- Total Revenue
- 32837.5
- Selling/ General/ Admin Expenses Total
- 14593.92
- Depreciation/ Amortization
- 2052.78
- Other Operating Expenses Total
- 771.72
- Total Operating Expense
- 28129.12
- Operating Income
- 4708.38
- Net Income Before Taxes
- 5009.59
- Net Income
- 3764.93
- Diluted Normalized EPS
- 16.54
- Period
- 2020
- Total Assets
- 68252.46
- Total Liabilities
- 22988.01
- Total Equity
- 45264.45
- Tangible Book Valueper Share Common Eq
- 135.14
- Period
- 2020
- Cashfrom Operating Activities
- 6554.77
- Cashfrom Investing Activities
- -2588.84
- Cashfrom Financing Activities
- -5715.14
- Net Changein Cash
- -1385.69
- Period
- 2019
- Total Revenue
- 29065.91
- Selling/ General/ Admin Expenses Total
- 12429.44
- Depreciation/ Amortization
- 1753.25
- Other Operating Expenses Total
- 741.09
- Total Operating Expense
- 25378.21
- Operating Income
- 3687.7
- Net Income Before Taxes
- 3810.2
- Net Income
- 2665.42
- Diluted Normalized EPS
- 15.61
- Period
- 2019
- Total Assets
- 64693.81
- Total Liabilities
- 23284.75
- Total Equity
- 41409.06
- Tangible Book Valueper Share Common Eq
- 121.28
- Period
- 2019
- Cashfrom Operating Activities
- 2241.97
- Cashfrom Investing Activities
- -681.25
- Cashfrom Financing Activities
- -2730.52
- Net Changein Cash
- -844.15
- Period
- 2018
- Total Revenue
- 26489.46
- Selling/ General/ Admin Expenses Total
- 11125.37
- Depreciation/ Amortization
- 1499.84
- Other Operating Expenses Total
- 700.9
- Total Operating Expense
- 23106.4
- Operating Income
- 3383.06
- Net Income Before Taxes
- 3478.98
- Net Income
- 2095.7
- Diluted Normalized EPS
- 12.84
- Period
- 2018
- Total Assets
- 64516.35
- Total Liabilities
- 26202.24
- Total Equity
- 38314.11
- Tangible Book Valueper Share Common Eq
- 114.99
- Period
- 2018
- Cashfrom Operating Activities
- 4026.88
- Cashfrom Investing Activities
- -3370.81
- Cashfrom Financing Activities
- -1539.26
- Net Changein Cash
- -735.91
- Period
- 2024-03-31
- Total Revenue
- 11982.9
- Selling/ General/ Admin Expenses Total
- 2299.34
- Depreciation/ Amortization
- 650.36
- Other Operating Expenses Total
- 4211.62
- Total Operating Expense
- 9643.37
- Operating Income
- 2339.53
- Net Income Before Taxes
- 2815.52
- Net Income
- 2654.58
- Diluted Normalized EPS
- 11.5
- Period
- 2024-03-31
- Total Assets
- 85462.88
- Total Liabilities
- 21796.13
- Total Equity
- 63666.75
- Tangible Book Valueper Share Common Eq
- 193.39
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 12136.27
- Cashfrom Investing Activities
- -690.2
- Cashfrom Financing Activities
- -6710.16
- Net Changein Cash
- 4661.92
- Period
- 2023-12-31
- Total Revenue
- 12380.7
- Selling/ General/ Admin Expenses Total
- 2363.32
- Depreciation/ Amortization
- 622.14
- Other Operating Expenses Total
- 3928.17
- Total Operating Expense
- 9720.38
- Operating Income
- 2660.32
- Net Income Before Taxes
- 3000.35
- Net Income
- 2523.75
- Diluted Normalized EPS
- 10.75
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 12192.41
- Selling/ General/ Admin Expenses Total
- 2364.36
- Depreciation/ Amortization
- 632.82
- Other Operating Expenses Total
- 3827.49
- Total Operating Expense
- 9611.76
- Operating Income
- 2580.65
- Net Income Before Taxes
- 2790.88
- Net Income
- 2375.51
- Diluted Normalized EPS
- 9.9
- Period
- 2023-09-30
- Total Assets
- 79441.16
- Total Liabilities
- 19615.52
- Total Equity
- 59825.64
- Tangible Book Valueper Share Common Eq
- 175.19
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 5719.95
- Cashfrom Investing Activities
- 993.7
- Cashfrom Financing Activities
- -5876.8
- Net Changein Cash
- 779.37
- Period
- 2023-06-30
- Total Revenue
- 11940.84
- Selling/ General/ Admin Expenses Total
- 2402.04
- Depreciation/ Amortization
- 651.32
- Other Operating Expenses Total
- 3450.9
- Total Operating Expense
- 9585.3
- Operating Income
- 2355.54
- Net Income Before Taxes
- 2481.14
- Net Income
- 2022.54
- Diluted Normalized EPS
- 9.49
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 10930.67
- Selling/ General/ Admin Expenses Total
- 2179.55
- Depreciation/ Amortization
- 671.53
- Other Operating Expenses Total
- 3671.6
- Total Operating Expense
- 8944.35
- Operating Income
- 1986.32
- Net Income Before Taxes
- 2239.69
- Net Income
- 1984.47
- Diluted Normalized EPS
- 8.96
- Period
- 2023-03-31
- Total Assets
- 80743.59
- Total Liabilities
- 24748.21
- Total Equity
- 55995.38
- Tangible Book Valueper Share Common Eq
- 158.19
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 5526.02
- Cashfrom Investing Activities
- -7943.68
- Cashfrom Financing Activities
- 2376.07
- Net Changein Cash
- 115.48
- Period
- 2022-12-31
- Total Revenue
- 11240.97
- Selling/ General/ Admin Expenses Total
- 2037.07
- Depreciation/ Amortization
- 659.95
- Other Operating Expenses Total
- 3393.38
- Total Operating Expense
- 8894.07
- Operating Income
- 2346.9
- Net Income Before Taxes
- 2471.47
- Net Income
- 2166.01
- Diluted Normalized EPS
- 9
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Sun Pharmaceutical Industries Technical
Moving Average
SMA
- 5 Day1471.94
- 10 Day1503.98
- 20 Day1511.53
- 50 Day1547.48
- 100 Day1490.48
- 300 Day1328.67
Sun Pharmaceutical Industries Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sun Pharmaceutical Industries
- 1453.25
- -6.9
- -0.47
- 1638.7
- 946.8
- 348683.35
- Cipla
- 1459.85
- 11.7
- 0.81
- 1519
- 941.85
- 117867.55
- Divis Laboratories
- 4320
- 10.05
- 0.23
- 4469.15
- 3300
- 114682.43
- Zydus Lifesciences
- 1032.25
- 31.55
- 3.15
- 1171.95
- 498.9
- 103844.35
- Dr Reddys Laboratories
- 5792.95
- 5.4
- 0.09
- 6505.5
- 4483.1
- 96469.12
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sun Pharmaceutical Industries
- 35
- 5.5
- 11.27
- 14.23
- Cipla
- 27.79
- 4.43
- 13.5
- 12.66
- Divis Laboratories
- 73.22
- 8.63
- 18.97
- 26.38
- Zydus Lifesciences
- 26.93
- 5.19
- 15.65
- 14.33
- Dr Reddys Laboratories
- 17.93
- 3.46
- 16.73
- 14.63
Sun Pharmaceutical Industries Shareholding
Shareholding Pattern
*Promoter pledging: 1.12%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 22-May-24
- Audited Results & Final Dividend
- 31-Jan-24
- Quarterly Results & Interim Dividend
- 01-Nov-23
- Quarterly Results
- 03-Aug-23
- Quarterly Results
- 26-May-23
- Audited Results & Final Dividend
- 31-Jan-23
- Quarterly Results & Interim Dividend
- 01-Nov-22
- Quarterly Results
- 29-Jul-22
- Quarterly Results
- 30-May-22
- Audited Results & Final Dividend
- 31-Jan-22
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 28-Aug-23
- 07-Jul-23
- AGM
- 29-Aug-22
- 03-Aug-22
- AGM
- 31-Aug-21
- 04-Aug-21
- AGM
- 16-Mar-21
- 05-Feb-21
- COM
- 27-Aug-20
- 29-Jul-20
- AGM
- 28-Aug-19
- 26-Jul-19
- AGM
- 04-Jun-19
- 30-Apr-19
- COM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 22-May-24
- -
- -
- 5
- 15-Jan-24
- 09-Feb-24
- 09-Feb-24
- 8.5
- 07-Jul-23
- 28-Jul-23
- 28-Jul-23
- 4
- 16-Jan-23
- 08-Feb-23
- 08-Feb-23
- 7.5
- 31-May-22
- 22-Aug-22
- 19-Aug-22
- 3
- 31-Jan-22
- 10-Feb-22
- 09-Feb-22
- 7
- 27-May-21
- -
- 23-Aug-21
- 2
- 29-Jan-21
- 10-Feb-21
- 09-Feb-21
- 5.5
- 27-May-20
- -
- 19-Aug-20
- 1
- 06-Feb-20
- 18-Feb-20
- 17-Feb-20
- 3
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)